/
Panamera Holdings Corporation ( Panamera or the Company ) was incorporated under the laws of the State of Nevada on May 20, 2014, as Panamera Healthcare Corporation. On October 21, 2021, we changed our name to Panamera Holdings Corporation and increased the number of our authorized shares from 200,000,000 shares to 600,000,000 shares, par value $0.0001 per share, of which 550,000,000 w…
$2.50
+$0.00 (+0.00%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-226.04% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 1129.1% YoY with margins expanding 77387.0pp.
Negative free cash flow of -$515K. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$189K
▲ +1129.1% YoY
Net Income (TTM)
-$154M
▲ +96.5% YoY
Op. Margin
-81688.33%
▲ +77387.0pp YoY
ROIC
-58381.83%
▲ +15175.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$593K
▼ -249.7% YoY
Op. Cash Flow (TTM)
-$593K
▼ -418.5% YoY
Net Debt
$35K
Cash & Equiv.
$46.00
3Y CAGR: +79.6%
Continue Research
Panamera Holdings (PHCI)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Panamera Holdings scores 15/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Panamera Holdings scores 15 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -81,688.3% operating margin and a -58,381.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh PHCI's valuation and scores 15/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.